Heartflow received nationwide UnitedHealthcare coverage for its AI CT plaque analysis software and announced plans for a $200M IPO at a $1.3B valuation.
Key Details
- 1UnitedHealthcare will provide nationwide coverage for Heartflow's CT-based plaque analysis software, effective October 1.
- 2Coverage applies to all UnitedHealthcare plans, including commercial, Medicare Advantage, and dual-eligible offerings.
- 3Heartflow aims to raise up to $212.5 million by offering 12.5 million shares at $15–$17 per share in its IPO.
- 4Company generated about $43 million in Q2 2025, up 40% year-over-year.
- 5Heartflow's platform has assessed over 400,000 patients for coronary artery disease as of March 31, 2025.
- 6The US market opportunity for Heartflow's products is estimated at $5 billion.
Why It Matters
Nationwide insurer coverage and a strong IPO position solidify Heartflow's AI solution as a standard in coronary CT interpretation. This represents a significant step in the adoption and reimbursement of radiology AI, paving the way for broader clinical and commercial implementation.
Source
Radiology Business
Related News
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.